

Treatment of unresolved lower back pain with platelet-rich plasma injections

Marc Darrow MD, Brent Shaw BS, Nicholas Schmidt BS, Xian Li BS and Gabby Boeger

Accepted Manuscript Version

This is the unedited version of the article as it appeared upon acceptance by the journal. A final edited version of the article in the journal format will be made available soon.

As a service to authors and researchers we publish this version of the accepted manuscript (AM) as soon as possible after acceptance. Copyediting, typesetting, and review of the resulting proof will be undertaken on this manuscript before final publication of the Version of Record (VoR). Please note that during production and pre-press, errors may be discovered which could affect the content.

© 2019 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license.

Publisher: Cogent OA

Journal: *Cogent Medicine*

DOI: <http://dx.doi.org/10.1080/2331205X.2019.1581449>

Accepted Manuscript

Treatment of unresolved lower back pain with platelet-rich plasma injections

Marc Darrow MD, Brent Shaw BS, Nicholas Schmidt BS, Xian Li BS, Gabby Boeger

Darrow Stem Cell Institute, 11645 Wilshire Blvd Suite 120, Los Angeles, CA 90025

Corresponding author: Marc Darrow, Email: marc@darrowsstemcells.com

Abstract

Background: Platelet-Rich Plasma (PRP) is a non-invasive modality that has been used to treat musculoskeletal conditions for the past two decades. Based on our research, there were no publications that studied the effect of PRP on unresolved lower back pain. The aim of this study was to report the clinical outcomes of patients who received PRP injections to treat unresolved lower back pain.

Methods: 67 patients underwent a series one, two, or three PRP injections into the ligaments, muscle, and fascia surrounding the lumbar spine. Patients who received two treatments received injections a mean 24 days apart and patients who received three treatments received injections a mean 20.50 days apart. Baseline and posttreatment outcomes of resting pain, active pain, lower functionality scale, and overall improvement percentage were compared to baseline and between groups.

Results: Patients who received one PRP injection reported 36.33% overall improvement and experienced significant improvements in active pain relief. These same patients experienced improvements in resting pain and functionality score, yet these results were not statistically significant. Patients who received a series of two and three treatments experienced significant decreases in resting pain and active pain and reported 46.17% and 54.91% total overall improvement respectively. In addition, they were able to perform daily activities with less difficulty than prior to treatment.

Conclusions:

These results demonstrate that PRP injections may be a viable conservative approach to treat lower back pain. Additional research is needed to confirm these findings.

Keywords: lower back pain, platelet-rich plasma, non-invasive modality, regenerative medicine, surgical alternative

Introduction

Low back pain (LBP) is one of the most common musculoskeletal issues, affecting over 25 million Americans, and costing in excess of 102 billion dollars each year [1-4]. Lifetime prevalence of LBP has been estimated to be as high as 84% [3]. However, chronic LBP that is defined as pain that lasts greater than 3 months is reported to have a 23% prevalence [5]. LBP may originate from multiple underlying etiologies creating a challenge for physicians. This uncertainty accounts for the continued rise in treatment costs without a similar increase in the number of office visits associated with LBP [4]. General recommendations for the treatment of LBP begins by ruling out serious pathoanatomical causes, such as spinal disease or radiculopathies, thereby leading to a diagnosis of non-specific back pain [5].

Magnetic resonance imaging (MRI) is used to rule out serious etiologies; however, it is not recommended for non-specific LBP due to a lack of evidence of improved symptoms and high false positives rates [6-9]. Studies have shown that abnormal MRI findings are present in up to 90% of asymptomatic patients due to normal aging and lead to unnecessary treatments that carry increased risks of adverse complications or side effects [6-9]. Despite recommendations, MRI orders for LBP continue to increase with a parallel increase in the rates of narcotic prescriptions, epidural steroid injections and surgical interventions, without an improvement in self-reported health status [2,8,10-15].

Platelet-rich plasma (PRP) therapy is a non-invasive, nonsurgical biologic intervention that has gained attention in the treatment of degenerative and musculoskeletal conditions [16,17]. PRP is isolated from autologous blood and contains an assortment of signaling cytokines that modulate inflammation and angiogenesis as well cell migration and proliferation, all of which are important in the healing process [18-21]. Studies have also found that PRP effects gene expression and downstream processes that produce pain. Thereby, PRP may play role in reducing or modulating the amount of pain produced by the body [22]. Due to these properties, patients with chronic non-specific LBP may experience therapeutic effects from PRP therapy.

It is well documented in research that PRP has demonstrated increased tendon and ligament healing through injections [23]. At our clinic we inject PRP into the muscles, fascia, and ligaments surrounding the lumbar spine to improve patients' spinal stability. Many of our patients may be diagnosed with herniated discs, facet arthropathy, degenerative disc disease, spinal stenosis, scoliosis, spondylosis, spondylolisthesis, or other pathology. We have found that the actual pain generator may not even be noted in the diagnosis. Strengthening the support of the spine may not only relieve patients' current pain regardless of the diagnosis but may lower their risk for future discogenic problems.

To our knowledge, PRP research for LBP has primarily focused on discogenic etiology. The goal of our study was to determine the therapeutic effect of PRP therapy for chronic non-specific LBP regardless of the diagnosis. Determining the clinical efficacy of PRP for the reduction of low back pain is essential to improve patient outcomes and prevent unnecessary and risky treatments.

Methods

Patients

This study reports clinical practice outcomes in which variables were administered prospectively and data were analyzed retrospectively. Patients who were included in this study underwent a series of one, two, or three PRP treatments for lower back pain. The procedures were performed at a solo practitioner private practice from July 2016 to April 2018. Patients who did not have at least one-month follow-up after the first injection were excluded. All treatments were prescribed on an individual basis, as recommended by a physician. Written informed consent was obtained prior to each treatment.

As stated in our previous knee osteoarthritis publication, [24] if a patient at our clinic requires multiple injections, we direct them to receive injections approximately fourteen days apart, however, scheduling conflicts often cause injection intervals more than fourteen days. At the fourteen day time period, there is growth factor secretion from various cell types that participate in the late phases of wound healing, which can enhance tissue regeneration [25,26]. Patients were instructed not to use non-steroidal anti-inflammatory drugs during treatment since they significantly impair platelet function [27]. In addition, they were instructed not to participate in any strenuous physical activity for the duration of treatment. Patient characteristics can be found in **Table 1**. This study was constructed to follow all ethical guidelines directed by the Declaration of Helsinki.

Procedure

48-cc of blood was drawn into six 8.5mL ACD solution A tubes. The blood was then spun in a centrifuge, and the top layer without visible red blood cells was isolated to yield 12-cc PRP. The PRP was then split into 4-cc portions and was added to three 6-cc syringes. 2-cc of Lidocaine was added to each syringe to ensure less post-injection stiffness. The injection sites were sterilized with 4% Hibiclens. The PRP was injected by the physician into the tender or painful

areas along the enthesis of the insertion of the quadratus lumborum, thoracodorsal fascia, iliac crest, interspinous and supraspinous ligaments, gluteus attachments to the pelvis, sacroiliac ligaments, etc, as determined per patient's complaints and tenderness.

Outcomes

The outcomes of interest in this study were changes to resting pain and active pain (numerical pain scale [NPS]), overall improvement (percentage scale), and function (scored questionnaire) as seen in **Figure 1**. Data was collected at follow-ups after each treatment and were performed at approximately one month, three months, six months, and annually after the first injection. The functionality portion of the questionnaire, which assessed the degree of difficulty in performing daily activities, was based on 10 of 20 activities assessed in the Lower Extremity Functional Scale, [28] but also included a “not applicable (N/A)” response option. This scale has been shown to be a reliable functionality questionnaire for LBP [29]. The NPS to assess resting and active pain used a scale of 0 (no pain) to 10 (extreme pain) [30]. Lastly, the form included a subjective measure of how much overall improvement the patient experienced following treatment on a scale of 0% to 100%.

Statistical Analysis

Baseline and postintervention data were compared using means and standard deviations. Each follow-up response was compared with its corresponding baseline response using the Wilcoxon signed rank test. Intergroup comparisons were performed using the Wilcoxon sum rank test. Covariates were not accessed in this report. Statistical significance was set at P less than 0.05 and statistical analysis was performed using R 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria).

Results

In total, there were 141 PRP treatments performed on 67 patients' lower backs. On average, patients had experienced 10.17 years of lower back pain prior to treatment. The two-treatment patients received injections a mean 24 days apart and the three treatment patients received injections a mean 20.50 days apart. Patient results can be found in **Tables 2-4 and Figure 2.**

Patients experienced successive decreases in resting and active pain with the increased number of PRP treatments. Patients who received one PRP injection reported a 1.13 (P=0.016) decrease in active pain, which is a 16.98% decrease compared to baseline. Patients who received a series of two PRP injections experienced a 1.20 (P=0.005) and 1.83 (P=0.002) decrease in resting pain and active pain respectively. That is a 31.15% decrease in resting pain and 26.34% decrease in active pain compared to baseline. Patients who received a series of three PRP treatments experienced a 1.91 (P=0.001) and 3.09 (P<0.001) decrease in resting and active pain respectively. That is a 51.85% decrease in resting pain and a 43.31% decrease in active pain compared to baseline. The three treatment group showed statistically significant results in terms of resting pain to the one treatment group and significant active pain relief compared to the one and two treatment group.

When patients were asked a percentage of overall improvement they also reported successive increases. Patients who received one treatment reported 36.33% total overall improvement, two treatment patients reported 46.17% total overall improvement, and three treatment patients reported 54.91% total overall improvement. 35 out of 67 patients experienced at least 50% overall improvement compared to baseline.

In terms of functionality score, two-treatment patients experienced less difficulty performing daily activities reporting a 6.16 (P=<0.001) increase, which is a 28.51% increase compared to baseline. Three treatment patients reported a 7.00 (P<0.001) increase in

functionality score, which is a 35.32% increase compared to baseline. The two and three-treatment groups experienced greater functionality score increases compared to the one-treatment group.

Discussion

Our study demonstrated that one, two or three PRP treatments were effective in significantly reducing active pain in the lower back. Additionally, functionality scores were significantly increased showing that patients were able to quickly return to everyday activities. Patients experienced an improvement in resting pain and functionality score after the one treatment, however, statistical significance was demonstrated only after the second and third treatments. Yet, self-reported mean total improvement was 36.33%, 46.17%, and 54.91% at the first, second and third treatments, respectively, suggesting an immediate clinical benefit.

Traditional treatments for chronic non-specific LBP include pharmacologic, steroid, or surgical interventions; however, the evidence for their efficacy is lacking and insufficient. For example, long-term controlled studies found that pharmacologic treatment for chronic LBP may only provide three months of relief and the overall quality of evidence was low [31]. Steroid injections are another common treatment, yet the FDA issued a drug safety warning in 2014 stating the effectiveness of steroid use has not been established and that there is potential for serious adverse effects. Furthermore, studies have shown that steroid injections were not suggested for chronic LBP lasting greater than six months and, overall, did not improve pain or disability [32,33].

PRP is fast, non-invasive procedure that has been studied as an alternative treatment modality for low back pain and musculoskeletal injuries in the recent decade. The physiologic complexity of PRP bestows characteristics intriguing to investigators that involve immunomodulatory effects as well as angiogenic properties that facilitate healing. The exact

mechanism of PRP is not known, but current research points to cytokines, growth factors and other proteins as the main medium through which PRP works [34]. Specifically, studies have shown that PRP contains vascular endothelial growth factor, epidermal growth factor, transforming growth factor β -1, platelet-derived growth factor, hepatocyte growth factor, insulin-like growth factor-I, basic fibroblast growth factor, and connective tissue growth factor responsible for significant tissue proliferation [34-36]. PRP also contains certain chemokines and cytokines that are involved in the innate inflammatory and immunologic response that facilitate healing [37]. Simultaneously, PRP modulates gene expression of specific chemokines that serve to regulate the immuno-inflammatory reaction, preventing disproportionate responses and reducing pain [22].

Tissue healing is a complex mechanism acting through multiple physiologic pathways that may require time for molecular recruitment to reach satisfactory levels to observe clinically beneficial effects. Our results indicated significant improvement in all measurable outcomes after a series of two treatments and showed continued improvement after three treatments. Based on these results, it could be hypothesized that with each successive treatment further improvement may be demonstrated due to increased molecular involvement. Furthermore, combining other treatment modalities known to act through similar pathways may enhance the effects of PRP and increase the rate of healing. For example, investigators have demonstrated that hyperbaric oxygen combined with platelet concentrate increases the rate of bone healing. [38] Further research is needed to explore these avenues; however, the promise of PRP in the treatment of chronic LBP and other degenerative health issues offers hope to patients that have failed conservative treatment and are unable to find relief of their symptoms.

The limitations of our study include the limited sample size in the group of patients that received a total of one treatment. The improvement in resting pain and functionality scores were not statistically significant, but perhaps with a larger sample size, pain scores may be significant even after one treatment. Another limitation to our study was the population studied. According to epidemiologic studies, risk factors for chronic lower back pain include low educational status and lower socioeconomic levels [39,40]. Most insurance companies do not cover PRP and subsequently our patient population may not be representative of the general population suffering from chronic low back pain. In addition, the conclusions of this study were limited by not accounting for all variables that may have influenced patient outcomes, such as comparing age and BMI between groups. However, we plan on addressing different covariates in a separate study at a later date. The subjectivity of the measured variables may have introduced response bias and there was no control group to account for a placebo effect of the injections. Further randomized-controlled studies with larger sample sizes and longer follow-ups are warranted to further validate these results.

Conclusion

Our study demonstrated that PRP therapy reduced pain and increased functionality in patients with chronic non-specific LBP. The results of the study offer promise to patients that have failed conservative modalities and seek a quick, non-invasive treatment. Further research is warranted to determine the efficacy of widespread implementation of PRP as the standard of care for chronic non-specific LBP and other related chronic health issues.

Conflict of Interest

Marc Darrow is the primary physician at Darrow Stem Cell Institute where all study procedures were performed.

REFERENCES

1. Nahin RL. Estimates of pain prevalence and severity in adults: United States. *J Pain*. 2012;16:769-780.
2. Martin BI, Turner JA, Mirza SK, Lee MJ, Comstock BA, Deyo RA. Trends in health care expenditures, utilization, and health status among US adults with spine problems, 1997–2006. *Spine*. 2009;34:2077-2084.
3. Balague F, Mannion AF, Pellise F, Cedraschi C. (2012). Non-specific back pain. *The Lancet*. 2012;379:482-491.
4. Bevers K, Hulla R, Rice O, Verdier G, Salas E, Gatchel RJ. The chronic low back pain epidemic in older adults in America. *J Pain Relief*. 2017;6.
5. Herndon CM, Zoberi KS, Gardner BJ. Common questions about chronic low back pain. *Am Fam Physician*. 2015;91:708-714.
6. Modic MT, Obuchowski NA, Ross JS, Brant-Zawadzki MN, Grooff PN, Mazanec DJ, Benzel EC. Acute low back pain and radiculopathy: MR imaging findings and their prognostic role and effect on outcome. *Radiology*. 2005;237:597-604.
7. Ash L, Modic M, Obuchowski N, Ross J, Brant-Zawadzki M, Grooff P. Effects of diagnostic information, per se, on patient outcomes in acute radiculopathy and low back pain. *Am J Neuroradiol*. 2008;29:1098-1103.
8. Jarvik JG, Hollingworth W, Martin B, et al. Rapid magnetic resonance imaging vs radiographs for patients with low back pain: A randomized controlled trial. *Jama*. 2003;289:2810–2818.
9. Chou R, Huffman LH. Nonpharmacologic therapies for acute and chronic low back pain: A review of the evidence for an American Pain Society/American College of Physicians Clinical Practice Guideline. *Ann Intern Med*. 2007;147:492.

10. Weiner DK, Kim Y, Bonino P, Wang T. Low back pain in older adults: Are we utilizing healthcare resources wisely? *Pain Med.* 2006;7:143-150.
11. Gray DT, Deyo RA, Kreuter W, Mirza SK, Heagerty PJ, Comstock BA, Chan L. Population-based trends in volumes and rates of ambulatory lumbar spine surgery. *Spine.* 2006;31:1957-1963.
12. Carrino JA, Morrison WB, Parker L, Schweitzer ME, Levin DC, Sunshine JH. Spinal injection procedures: volume, provider distribution, and reimbursement in the U.S. Medicare population from 1993 to 1999. *Radiology.* 2002;225:723-729.
13. Friedly J, Chan L, Deyo R. Increases in lumbosacral injections in the Medicare population. *Spine.* 2007;32:1754-1760.
14. Luo X, Pietrobon R, Hey L. Patterns and trends in opioid use among individuals with back pain in the United States. *Spine.* 2004;7:300.
15. Martin BI, Deyo RA, Mirza SK, Turner JA, Comstock BA, Hollingworth W. Expenditures and health status among adults with back and neck problems. *Jama.* 2008;299:2630.
16. Andia I, Abate M. Platelet-rich plasma: Underlying biology and clinical correlates. *Regen Med.* 2013;8:645-658.
17. Andia I, Latorre PM, Gomez MC, Burgos-Alonso N, Abate M, Maffulli N. Platelet-rich plasma in the conservative treatment of painful tendinopathy: A systematic review and meta-analysis of controlled studies. *Br Med Bull.* 2014;110:99-115.
18. Andia I, Sanchez M, Maffulli N. Tendon healing and platelet-rich plasma therapies. *Expert Opin Biol Ther.* 2010;10:1415-1426.

19. Bosch G, Moleman M, Barneveld A, Weeren PR, Schie HT. The effect of platelet-rich plasma on the neovascularization of surgically created equine superficial digital flexor tendon lesions. *Scand J Med Sci Sports*. 2011;21:554-561.
20. Lyras DN, Kazakos K, Verettas D, Polychronidis A, Tryfonidis M, Botaitis S, Patsouris E. The influence of platelet-rich plasma on angiogenesis during the early phase of tendon healing. *Foot Ankle Int*. 2009;30:1101-1106.
21. Lyras D, Kazakos K, Verettas D, Polychronidis A, Simopoulos C, Botaitis S, Patsouris E. Immunohistochemical study of angiogenesis after local administration of platelet-rich plasma in a patellar tendon defect. *Int Orthop*, 2010;34:143-148.
22. Andia I, Rubio-Azpeitia E, Maffulli N. Platelet-rich plasma modulates the secretion of inflammatory/angiogenic proteins by inflamed tenocytes. *Clin Orthop Relat Res*. 2015;473:1624-1634.
23. Yuan T, Zhang C-Q, Wang JH-C. Augmenting tendon and ligament repair with platelet-rich plasma (PRP). *Muscles, Ligaments and Tendons Journal*. 2013;3(3):139-149.
24. Shaw B, Darrow M, Derian A. Short-Term Outcomes in Treatment of Knee Osteoarthritis With 4 Bone Marrow Concentrate Injections. *Clinical Medicine Insights Arthritis and Musculoskeletal Disorders*. 2018;11:1179544118781080. doi:10.1177/1179544118781080.
25. Enoch S, Price PE. Cellular, molecular and biochemical differences in the pathophysiology of healing between acute wounds, chronic wounds, and wounds in the aged. *World Wide Wounds* August 2004;
26. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. *Wound Repair Regen*. 2008;16(5):585-601. doi:10.1111/j.1524-475X.2008.00410.x

27. Schippinger G, Prüller F, Divjak M, et al. Autologous Platelet-Rich Plasma Preparations: Influence of Nonsteroidal Anti-inflammatory Drugs on Platelet Function. *Orthopaedic Journal of Sports Medicine*. 2015;3(6):2325967115588896. doi:10.1177/2325967115588896.
28. Binkley JM, Stratford PW, Lott SA, Riddle DL. The Lower Extremity Functional Scale (LEFS): scale development, measurement properties, and clinical application. North American Orthopaedic Rehabilitation Research Network. *Phys Ther*. 1999;79(4):371–83.22.
29. Liang HW, Hou WH, Chang KS. Application of the modified Lower Extremity Functional Scale in low back pain. *Spine(Phila Pa 1976)*. 2013; 38: 2043– 2048.
<http://dx.doi.org/10.1097/BRS.0b013e3182a826e8>
30. Childs JD, Piva SR, Fritz JM. Responsiveness of the numeric pain rating scale in patients with low back pain. *Spine (Phila Pa 1976)* 2005;30(11):1331–4. doi:
31. Kuijpers T, Middelkoop MV, Rubinstein SM, Ostelo R, Verhagen A, Koes BW, Tulder MW. A systematic review on the effectiveness of pharmacological interventions for chronic non-specific low-back pain. *Eur Spine J*. 2011;20:40-50.
32. Chou R, Hashimoto R, Friedly J, Fu Rochelle, Dana T, Sullivan S, Bougatsos C, Jarvik J. Pain management injection therapies for low back pain. Technology assessment report ESIB0813. (Prepared by the Pacific Northwest Evidence-based Practice Center under contract no. HHS-2012-00014-I.) Rockville, MD: Agency for Healthcare Research and Quality; 2015.
33. Choi HJ, Hahn S, Kim CH, Jang BH, Park S, Lee SM, Park B. Epidural steroid injection therapy for low back pain: A meta-analysis. *Int J Technol Assess Health Care*. 2013;29:244-253.

34. Dechellis DM, Cortazzo MH. Regenerative medicine in the field of pain medicine: Prolotherapy, platelet-rich plasma therapy, and stem cell therapy—Theory and evidence. *Tech Reg Anesth Pain Manag.* 2011;15:74-80.
35. Sys J, Weyler J, Zijden TV, Parizel P, Michielsen J. Platelet-rich plasma in mono-segmental posterior lumbar interbody fusion. *Eur Spine J.* 2011;20:1650-1657.
36. Anitua E, Andí I, Sanchez M, Azofra J, Zalduendo MD, Fuente MD, Nurden AT. Autologous preparations rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture. *J Orthop Res.* 2005;23:281-286.
37. Galliera E, Corsi M, Banfi G. Platelet rich plasma therapy: Inflammatory molecules involved in tissue healing. *J biol regul homeost agents.* 2011;26:35-42.
38. Neves P, Abib S, Neves R, Pircchio O, Saad K, Saad P, Laurino C. Effect of hyperbaric oxygen therapy combined with autologous platelet concentrate applied in rabbit fibula fraction healing. *Clinics.* 2013;68:1239-1246.
39. Hoy D, Brooks P, Blyth F, Buchbinder R. The epidemiology of low back pain. *Best Pract Res Clin Rheumatol.* 2010;24:769–81.
40. Unde Ayvat P, Aydin ON, Ogurlu M. Risk factors associated with lower back pain in the Polyclinic of Algology. *Agri.* 2012;24:165-70.

Table 1. Patient Characteristics

	N	Mean (SD)
Age	67	53.51 (16.52)
BMI	67	26.90 (5.66)
Years of Pain	67	10.17 (11.32)
Gender %		
Female	27	40.30%
Male	40	59.70%

Accepted Manuscript

Table 2. The Baseline and Post-Treatment Scores of Patients who received 1 PRP Treatments for Lower Back Pain. N=15

Number of Treatments	0	1	Difference	P-Value	Percent Difference
Resting Pain (0-10) Mean (SD)	3.67 (2.99)	3.13 (2.97)	-0.53	0.200	14.55%
Active Pain (0-10) Mean (SD)	6.73 (2.69)	5.60 (3.22)	-1.13	0.016	16.83%
Total Improvement (0-100%) Mean (SD)	-	36.33% (39.64)			36.33%
Functionality Score (0-40) Mean (SD)	20.60 (12.94)	21.80 (13.24)	1.20	0.130	5.83%
Follow up Time (mo.)	7.28				

Table 3. The Baseline and Post-Treatment Scores of Patients who received a series of 2 PRP Treatments for Lower Back Pain. N=30

	0	2	Difference	P-Value	Percent Difference
Resting Pain (0-10) Mean (SD)	3.70 (2.39)	2.50 (2.52)	-1.20	0.005	32.47%
Active Pain (0-10) Mean (SD)	6.33 (2.67)	4.50 (3.30)	-1.83	0.002	28.95%
Total Improvement (0-100%) Mean (SD)	-	46.17% (36.24)			46.17%
Functionality Score (0-40) Mean (SD)	21.63 (8.12)	28.10 (9.84)	6.47	<0.001	29.89%
Follow up Time (mo.)	5.41				
Days between Injections	24.00				

Table 4. The Baseline and Post-Treatment Scores of Patients who received a series of 3 PRP Treatments for Lower Back Pain. N=22

Number of Treatments	0	3	Difference	P-Value	Percent Difference
Resting Pain (0-10) Mean (SD)	3.68 (2.87)	1.77 (3.90)	-1.91	0.001	51.85%
Active Pain (0-10) Mean (SD)	7.14 (2.08)	4.05 (2.77)	-3.09	<0.001	43.31%
Total Improvement (0-100%) Mean (SD)	-	54.91% (35.17)			54.91%
Functionality Score (0-40) Mean (SD)	19.82 (7.81)	26.82 (7.63)	7.00	<0.001	35.32%
Follow up Time (mo.)	4.22				
Days Between Injections	20.50				

Figure 1. Patient Questionnaire

Lower Extremity Functionality Questions

Please describe the degree of difficulty you have performing these activities with your injured lower body part

	Activities	Extreme Difficulty	Quite a Bit of Difficulty	Moderate Difficulty	A Little Bit of Difficulty	No Difficulty	N/A
1	Job, housework, or school activities	0	1	2	3	4	N/A
2	Hobbies, recreational, or sport activities	0	1	2	3	4	N/A
3	Squatting	0	1	2	3	4	N/A
4	Walking two blocks	0	1	2	3	4	N/A
5	Going up stairs	0	1	2	3	4	N/A
6	Rolling over in bed	0	1	2	3	4	N/A
7	Standing for an extended period of time	0	1	2	3	4	N/A
8	Lifting a heavy objecting	0	1	2	3	4	N/A
9	Getting in and out of your car	0	1	2	3	4	N/A
10	Bending to the floor	0	1	2	3	4	N/A

Total: _____


Resting Pain Level: 0 1 2 3 4 5 6 7 8 9 10
(No pain) (Extreme pain)

Active Pain Level: 0 1 2 3 4 5 6 7 8 9 10
(No pain) (Extreme pain)

Improvement Since Date of First Treatment (%) 0 10 20 30 40 50 60 70 80 90 100

Figure 2. Comparing Relief of Active Pain, Resting Pain, Total Overall Improvement Percentage, and Functionality Score by Treatment Number

Percent Relief Between Treatments



Legend:

1-Statistically significant ($P < .05$) compared with outcomes after first injection.

2-Statistically significant ($P < .05$) compared with outcome after second injection.

Accepted Manuscript

Public Interest Statement:

Low back pain is one of the most common musculoskeletal issues, plaguing over 25 million Americans, and costing in excess of 102 billion dollars each year. Patients ailing from this condition are forced to choose from the conservative treatments, which are unreliable and invasive surgeries. The objective of this study was to provide insight on a minimally invasive surgical alternative that uses components of a patient's own blood to regrow tissue and relieve pain, called Platelet-Rich Plasma (PRP) Therapy. PRP therapy has been used for the past two decades for different musculoskeletal conditions. To our knowledge, this is the first study that examined PRP's clinical effect on lower back pain when injected into the ligaments, muscles, and fascia surrounding the lumbar spine. Our hope is by providing continual research about the efficacy of regenerative medicine it can reach and educate more people.

About the Author:

The authors of this study are apart of a private clinical practice called the Darrow Stem Cell Institute, which treats degenerative musculoskeletal conditions and sports injuries with regenerative medicine therapies. Our research department is dedicated to educate both the medical community and our patients about the efficacy of regenerative medicine with our clinical practice outcomes. This will be our 4th publication in the treatment of different musculoskeletal conditions with Bone Marrow Concentrate and Platelet-Rich Plasma Therapies.